Sartor Oliver, Parker Christopher C, de Bono Johann
Department of Urology and Medicine, Tulane Medical School, Tulane, New Orleans, Louisiana, USA.
Asian J Androl. 2014 Sep-Oct;16(5):666. doi: 10.4103/1008-682X.133314.
Recent reports and discussions of preclinical prostate cancer models have emphasized the possibility that enzalutamide resistance may be mediated by glucocorticoid receptors (GR). In both in vitroand xenograft animal studies, it is possible to show that the GR is up-regulated in prostate cancer cell lines and that dexamethasone reverses enzalutamide induced growth inhibition. In these model systems, GR agonists can induce a subset of androgen receptor target genes including prostate-specific antigen. These investigators also report a correlation between GR expression in patient-derived prostate cancer specimens and clinical response to enzalutamide. The authors discuss the possibility that these findings have important clinical relevance. We note that the current clinical evidence for GR mediating drug resistance or disease progression in patients with castrate-resistant prostate cancer (CRPC) is very limited at best.
最近关于临床前前列腺癌模型的报告和讨论强调了恩杂鲁胺耐药性可能由糖皮质激素受体（GR）介导的可能性。在体外和异种移植动物研究中，都有可能表明GR在前列腺癌细胞系中上调，并且地塞米松可逆转恩杂鲁胺诱导的生长抑制。在这些模型系统中，GR激动剂可诱导雄激素受体靶基因的一个子集，包括前列腺特异性抗原。这些研究人员还报告了患者来源的前列腺癌标本中GR表达与对恩杂鲁胺的临床反应之间的相关性。作者讨论了这些发现具有重要临床意义的可能性。我们注意到，目前关于GR介导去势抵抗性前列腺癌（CRPC）患者耐药或疾病进展的临床证据充其量非常有限。
